Subject(s)
Dermoscopy , Humans , Dermoscopy/methods , Diagnosis, Differential , Skin Neoplasms/pathology , Skin Neoplasms/diagnosis , Male , Female , Skin/pathologySubject(s)
Dermoscopy , Humans , Dermoscopy/methods , Diagnosis, Differential , Skin Neoplasms/pathology , Skin Neoplasms/diagnosis , Male , Female , Skin/pathologySubject(s)
Balanitis , Cyclosporine , Balanitis/diagnosis , Balanitis/drug therapy , Humans , Male , OintmentsABSTRACT
BACKGROUND: The management of melasma remains a challenge in dermatology, despite the availability of a variety of therapies, such as sunscreens, hypopigmented topical treatments, and chemical peels. The ideal treatment for melasma should be efficient, conclusive, and free from side effects. OBJECTIVE: The aim of this study is to assess the efficacy and tolerability of a depigmenting agent complex, based on the synergy of oligopeptide-68, phytic acid, glycolic acid, lactic acid, and octinoxate measured by clinical and reflectance confocal microscopy outcomes in melasma patients. METHODS: Twenty female patients exhibiting clinical evidence of melasma, aged between 29 and 61 years, were randomly enrolled in the study. Reflectance confocal microscopy was performed at baseline and after three months of treatment. RESULTS: Clinically, all patients showed significant improvement in melasma after treatment without adverse reactions. A relevant improvement in the treated skin areas was also assessed using reflectance confocal microscopy analysis. CONCLUSION: This study suggests that a combination of topical agents containing oligopeptide-68, phytic acid, glycolic acid, lactic acid, and octinoxate produces significant rapid improvement in melasma at clinical and cellular levels.